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The combination of brain imaging and genetics promises to identify neural mechanisms underlying complex
traits such as cognition and psychiatric disorder. The study by Heck et al. (2014) in this issue of Neuron
highlights voltage-gated cation channel activity as a likely link and culprit.Disorders such as schizophrenia and
mood disorders account for more than
15% of all days lived with disability but
have so far been slow to reveal their
underlying neural mechanisms. Cognitive
decline—most often first seen as loss of
short-term, or working, memory—is a
common fear in aging, presaging demen-
tia. Patients with schizophrenia consis-
tently show significant deficits in working
memory, as to a lesser extent do patients
with bipolar disorder. How might mecha-
nisms underlying psychiatric conditions
such as schizophrenia be related to the
universal trait of cognition? We know
that both have a substantial genetic
component. At the most recent count,
some 20% of the genetic variance in
schizophrenia has been ascribed to
around 100 genes, each contributing a
very small incremental increase to risk
(Ripke et al., 2013). There is evidence
for a significant polygenic component
(aggregate impact of many genetic vari-
ants each of small effect) and for genetic
overlap between schizophrenia and
bipolar disorder (Purcell et al., 2009).
Both of these disorders have a cognitive
component. There is likewise evidence
for a significant polygenic component
to cognition in the normal population
(Davies et al., 2011) and to cognitive
change over the life course (Deary et al.,
2012). Moreover, there is evidence for
shared genetic architecture between
schizophrenia and general cognitive
ability (McIntosh et al., 2013). But which
genes matter most? To date, APOE is
the best, but perhaps only, example of
a candidate gene that is reliably andconsistently associated with cognitive
functions, explaining2% of the variance
(Wisdom et al., 2011). Other candidate
genes almost always fail to replicate
(Payton, 2009; Chabris et al., 2012),
most likely because this well-measured
trait is the compound of many different
gene functions, each of small effect, and
with no two individuals inheriting quite
the same set. The chance of any one
variant rising to the top in a genetic asso-
ciation study will be slight. Herein lies
the (at least) 2-fold problem for cognition,
true also for many other complex traits,
namely of phenotypic heterogeneity
and of specificity generality—how direct
(causal) is the trait association and how
specific is it to the trait measured? Both
problems are relevant to the report by
Heck et al. (2014) in the current edition
of Neuron.
The n-back task (Gevins and Cutillo,
1993) is the gold standard brain-imaging
task to assess working memory. It is a
test of ordered memory recall of letter
sequences; the 0-back task sets the
baseline and the 2-back tests the ability
to recall the letter that was 2 steps back
in the order presented. Using the 2-back
test of working memory as a quantitative
trait, Heck et al. (2014) took an agnostic
view and surveyed the whole genome for
common SNPs that were significantly
associated with a deficit in working
memory, as defined by the 2-back test.
They found five such SNPs, four clustered
on chromosome 12, spanning PAWR, a
brain-expressed transcriptional regulator,
and one on chromosome 1, within an
intron of OLFM3, encoding olfactomedin.NeuronThat may seem like poor pickings from an
analysis of a reassuringly large discovery
set of 905 healthy participants but was
really a side show, not developed further,
to the real substance of the study.
Standard practice would be to repeat
the analysis directly in one or more cohort
with equivalent measures. They do report
evidence for replication, in two indepen-
dent cohorts, but by a relatively novel
approach and with caveats to which
we will return later. First, they took the
GWAS data from the discovery set of
905 individuals and transformed the data
into a gene set enrichment analysis.
Here, rather than just look at those few
individual SNPs that pass an agreed
threshold for genome-wide significance,
the idea is to take a more inclusive
approach from a more functional per-
spective. In gene set enrichment, you first
assign each SNP to the most proximal
gene in the genome, take the most
significant associations, and sort the
genes by functional annotation. Now
you can ask, do any ontologies rise to
the surface as significantly associated
with working memory? The answer was
yes. Two out of the comprehensive set
of 1,411 tested exceeded the false dis-
covery test of significant association.
These were ‘‘voltage-gated cation chan-
nel activity’’ (GO:0022843) and ‘‘transport
of glucose and other sugars, bile salts
and organics acids, metal ions and
amine compounds’’ (Reactome). Given
the objective of the study, you have to
like the look of the first class, because
these channels are known to regulate
neuronal excitability, but what can you81, March 5, 2014 ª2014 Elsevier Inc. 959
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blessing and the curse of the general
approach—gene ontologies reflect the
state of knowledge about gene function,
which is both limited and biased by virtue
of the foregoing research. Even those
that survive the false discovery tests will
inevitably include false positives. Inde-
pendent replication is essential.
Inspection of GWAS data in two
other well-sized cohorts (n = 746 and
n = 410) with brain imaging and proxies
for measures of working memory found
supporting genetic evidence for the
‘‘voltage-gated cation channel activity’’
gene set, but not the ‘‘reactome,’’ so
that was encouraging. It is important
to acknowledge that there is some con-
troversy around genome enrichment
analysis software—which works best
and how robust are the outputs—but the
‘‘voltage-gated cation channel activity’’
finding did replicate across multiple soft-
ware platforms.
However, there is a bigger caveat that
poses a wider and provocative question:
the replication sets did not have identical
cognitive measures. The Zurich sample
of younger adults took the Wechsler for-
ward digit span task, and the AgeCoDe
sample of cognitively healthy elder sub-
jects took aword list learning task. Neither
of these tasks would normally be viewed
as a test of working memory: backward
digit span or letter-number sequencing
are those Wechsler tasks that are some-
times called working memory, and word
list learning is typically thought of as
verbal declarative memory. In any case,
these tests have modest phenotypic
correlations with the n-back task. This
cuts two ways for Heck et al. (2014). If
there were failure to replicate from the
n-back studies to Zurich and AgeCoDe,
then one might simply appeal to pheno-
typic heterogeneity. In other words, the
so-called attempt at replication was, in
fact, addressing a different phenotype.
However, to the extent that there is
some replication to Zurich and AgeCoDe
forces us to consider whether the results
tell us something more about cognition
than just working memory. It is well estab-
lished that variation in cognitive tests
comes from at least three sources: gen-
eral cognitive ability, domain-specific
cognitive ability, and task-specific cog-
nitive ability (Deary et al., 2010). Thus,960 Neuron 81, March 5, 2014 ª2014 Elseviewhen a person performs well in, say, the
n-back task, this might be because they
are good at all cognitive tests, and/or
good at memory tests in general, and/or
especially good at the n-back task.
And we must add to this that working
memory tasks are quite strongly loaded
on general cognitive ability and that
working memory and general cognitive
ability have a strong genetic correlation
(Goldberg et al., 2013). Therefore, before
we conclude that Heck et al. (2014) have
only told us something specific about
working memory, we should test whether
they have, in fact, told us something
about memory in general or about general
cognitive ability variation.
The link between working memory and
voltage-gated cation channel activity is
not only biologically plausible, it is also
consistent with their own and other recent
findings from psychiatric genetics. They
report a robust replication for the asso-
ciation in a publicly available GWAS
data set from the Psychiatric Genetics
Consortium’s analysis of schizophrenia
in a large Swedish case-control study
(Ripke et al., 2013). This should not
perhaps come as too great a surprise as
one prominent member of this gene set
is CACNA1C, known to harbor variants
that confer risk to schizophrenia (Ripke
et al., 2013). Adding further weight to
the finding, the Psychiatric Genetics
Consortium recently reported an in-
creased burden of rare coding variants
in this gene set (Purcell et al., 2014).
Heck et al. (2014) further show that the
‘‘voltage-gated cation channel activity’’
gene set regulates cortical activity during
a working (but not episodic) memory
fMRI paradigm. The imaging sample was
selected from individuals within the repli-
cation sample, rather than being selected
completely independently of the other
findings, so that warrants further work.
What is also currently lacking is a clear
link from gene set enrichment through
brain activity to working memory task
performance outside of the scanner. This
could be remedied in future studies by
employing measures where the within-
scanner task-associated activations and
‘‘real-life’’ performance are more highly
correlated.
To conclude, this study substantially
raises the bar for future functional
imaging studies of genetic variants. It isr Inc.rigorous in its methodology and sample
size. The relevance to schizophrenia has
been highlighted and the value of fMRI
studies that might tease out the brain
circuitry is signaled if not yet fully devel-
oped. Combining state-of-the-art func-
tional brain imaging with large study sam-
ples and genomic analysis is however
very challenging. While this effort
is important for our mechanistic under-
standing of brain function, cognition,
and mental illness, such well-founded
samples sets are few and far between.
Efforts to combine and standardize
large imaging samples are underway
(such as ENIGMA [Thompson et al.,
2014] and the Human Connectome
project [Van Essen et al., 2013]). The UK
Biobank has initiated pilot body and brain
imaging studies, which if successful
will extend to as many as 100,000 of this
500,000 strong cross-sectional case-
control cohort (http://www.ukbiobank.
ac.uk/2013/09/uk-biobank-welcomes-
imaging-funding/). These consortia will
focus on structural and connectivity
measures that can be generalized across
multiple centers to better describe the
human brain ‘‘connectome.’’ These
efforts promise to bring the same ‘‘big
data’’ approaches, openness, and meth-
odological rigor to imaging science that
has led to step changes in progress to
detect and define genome associations
with disease and disease-related traits
through the formation of international
consortia. In this regard, the study by
Heck et al. (2014) is a real step forward
in brain imaging genomics.REFERENCES
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Motor neurons in ALS die via cell-autonomous and non-cell-autonomous mechanisms. Using adult human
astrocytes and motor neurons, Re et al. (2014), in this issue of Neuron, discover that familial and sporadic
ALS-derived human adult astrocytes secrete neurotoxic factors that selectively kill motor neurons through
necroptosis, suggesting a new therapeutic avenue.Amyotrophic lateral sclerosis (ALS),
commonly referred to as Lou Gehrig’s
disease, is an adult-onset neurodegener-
ative disease manifested by degenera-
tion of motor neurons in motor cortex,
brain stem, and spinal cord, resulting in
muscle paralysis and ultimately death
(Rowland and Shneider, 2001). While
the disease is dominantly inherited in
approximately 10% of patients (termed
familial), most often the disease is spo-
radic, with largely unknown genetic etiol-
ogy. Numerous hypotheses have been
proposed to account for the disease-
associated motor neuron loss, including
conformational instability of proteins
triggering neurotoxicity, perturbations of
RNA processing, mitochondrial dysfunc-
tion, defective axonal transport, excito-toxicity, and inflammation (reviewed in
(Rothstein, 2009). However, the precise
molecular mechanism(s) that target mo-
tor neurons for death and result in the
pathological manifestations still remain
elusive. Studies reporting mutations in
the SOD1 gene encoding the antioxidant
enzyme Cu/Zn superoxide dismutase-1
provided the first genetic link to ALS
(Rosen et al., 1993). Since then, studies
have implicated both cell-autonomous
and non-cell-autonomous mechanisms
in SOD1-mediated toxicity (Clement
et al., 2003). The identity of such cell
types that modulate motor neuron sur-
vival came from studies using cultured
motor neurons derived from embryonic
spinal cord or differentiated from embry-
onic stem cells (Di Giorgio et al., 2008;Marchetto et al., 2008; Nagai et al.,
2007). In these studies, cocultured motor
neurons were less likely to survive when
they were on astrocytes that express
mutant SOD1. Exposure of cultured mo-
tor neurons to conditioned media derived
from astrocytes also affected survival of
motor neurons, probably through soluble
factors released by mutant SOD1-
expressing astrocytes. In coculture sys-
tems with motor neurons, astrocytes
derived from sporadic ALS (sALS) post-
mortem spinal cord neural progenitor
cells (NPCs) also selectively killed motor
neurons (Haidet-Phillips et al., 2011),
suggesting a shared astrocyte-depen-
dent disease mechanism between famil-
ial and sporadic forms of ALS. While
these studies point to astrocytes as81, March 5, 2014 ª2014 Elsevier Inc. 961
